



# Prior Authorization Request Form for Antibiotics, GI and Related Agents

FAX this completed form to (844) 386-4695

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

OR Prior authorization may be completed at <https://www.covermyeds.com/main/prior-authorization-forms/>

I. PROVIDER INFORMATION		II. MEMBER INFORMATION	
Prescriber Name:		Member Name:	
Prescriber Specialty:		Identification #:	
NPI:		Group #:	
Office Contact Name:		Date of Birth:	
Fax #:		Medication Allergies:	
Phone #:			
III. DRUG INFORMATION (One drug request per form)			
Drug name and strength:		Dosage Interval (sig):	Qty. per Day & Duration:
IV. REQUIRED DOCUMENTATION (Detailed medical record documentation demonstrating evidence for each item must be submitted with prior authorization request)			
Specify diagnosis & diagnosis code relevant to this request:		Dx/Dx Code: _____	
<b>Requests for all non-preferred medications:</b> Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Antibiotics, GI and Related Agents? Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes Medications Taken Previously (start and end date and dose): _____ <input type="checkbox"/> No _____	
<input type="checkbox"/> If requesting for daily quantity exceeding daily limit (Refer to <a href="https://www.pahealthwellness.com/providers/pharmacy.html">https://www.pahealthwellness.com/providers/pharmacy.html</a> under PHW Quantity Limit List), please provide supporting information: _____			
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.			
<b>DIFICID (FIDAXOMICIN):</b>			
<input type="checkbox"/> For the treatment of <i>Clostridioides difficile</i> infection (CDI), one of the following: <ul style="list-style-type: none"> <li><input type="checkbox"/> Has at least one of the following factors associated with a high risk of recurrence of CDI:             <ul style="list-style-type: none"> <li><input type="checkbox"/> Age ≥65 years</li> <li><input type="checkbox"/> Clinically severe CDI (Zar score ≥ 2): _____</li> <li><input type="checkbox"/> Is immunocompromised</li> </ul> </li> <li><input type="checkbox"/> Has a recurrent episode of CDI</li> <li><input type="checkbox"/> Is prescribed Dificid (fidaxomicin) as a continuation of therapy upon inpatient discharge</li> </ul>			
<b>TRAVELERS' DIARRHEA:</b>			
<input type="checkbox"/> History of therapeutic failure, contraindication or intolerance to Azithromycin (start date and end date): _____			
<b>HEPATIC ENCEPHALOPATHY:</b>			
<input type="checkbox"/> History of therapeutic failure, contraindication or intolerance to Lactulose: _____			
<b>IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) OR SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO):</b>			
<input type="checkbox"/> Prescribed by or in consultation with a gastroenterologist			

**ZINPLAVA (BEZLOTOXUMAB):**

- Prescribed by or in consultation with a gastroenterologist or infectious disease specialist
- Has a recent stool test positive for toxigenic *Clostridioides difficile*
- Has at least one of the following factors associated with a high risk for recurrence of *Clostridioides difficile* infection (CDI):
  - Age ≥65 years
  - Extended use of one or more systemic antibacterial drugs: \_\_\_\_\_
  - Clinically severe CDI (Zar score ≥ 2): \_\_\_\_\_
  - At least one previous episode of CDI within the past 6 months or a documented history of at least 2 previous episodes of CDI: \_\_\_\_\_
  - Is immunocompromised
  - The presence of a hypervirulent strain of CDI bacteria (ribotypes 027, 078, or 244)
- Is prescribed Zinplava (bezlotoxumab) in conjunction with an antibiotic regimen that is consistent with the standard of care
- Has not received a prior course of treatment with Zinplava (bezlotoxumab)

**IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) RENEWAL REQUESTS:**

- Member has experienced a successful initial treatment course
- Member has documented recurrence of IBS-D symptoms
- Member has not received 3 treatment courses with Xifaxan in lifetime

**IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :**

Empty box for providing additional rationale or clinical information.

Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:
--	---------------------	-------

Pharmacy Department will respond via fax or phone within 24 hours.  
Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)